Compare GSK plc (GSK) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs MPLX LP — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while MPLX LP trades at $56.35 (market cap $58.11B). The key difference: GSK plc is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| GSK | MPLX | |
|---|---|---|
Market Cap | $91.88B | $58.11B |
Volume | 7,730,529 | 687,483 |
Sector | Health | Energy |
52-Week High | $61.18 | $60.51 |
52-Week Low | $43.24 | $47.80 |
Typical Hold Time | 93 Days | — |
Enterprise Value | $111.88B | $83.22B |
Dividend Yield | 3.9% | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
MPLX trades at $56.30, down 1.31% today, with a bearish technical signal and mixed earnings history including a recent Q2 2026 EPS miss. The company maintains strong profitability with a 40.45% net income margin and robust cash flow, supporting a $1.08 dividend. Analyst consensus is bullish with a $63.80 price target, though technical indicators show near-term resistance at $58.
The outlook for MPLX is positive due to its fee-based revenue model, high dividend yield, and analyst support, but risks include energy market volatility and recent earnings misses. Investors may find value in its cash flow stability, though caution is warranted given bearish technical trends and macroeconomic pressures on the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
